The company reported a net profit of Rs 10 crore in the corresponding quarter of the previous year.
Revenue from operation rose 13% year-on-year (YoY) to Rs 2,204 crore in Q3FY25.
EBITDA rose 6% YoY to Rs 350 crore, while EBITDA margins dropped 100 basis points to 16%.
The contract research and manufacturing services (CDMO) revenues rose 13% YoY to Rs 1,278 crore led by continued traction in the on-patent commercial manufacturing and generic active pharmaceutical ingredient (API) business.
-
Stock Trading
Maximise Returns by Investing in the Right Companies
-
Stock Trading
Market 104: Options Trading: Kickstart Your F&O Adventure
-
Stock Trading
Technical Analysis for Everyone – Technical Analysis Course
-
Stock Trading
Stock Markets Made Easy
-
Stock Trading
Renko Chart Patterns Made Easy
-
Stock Trading
Market 101: An Insight into Trendlines and Momentum
-
Stock Trading
Markets 102: Mastering Sentiment Indicators for Swing and Positional Trading
-
Stock Trading
Dow Theory Made Easy
-
Stock Trading
Market 103: Mastering Trends with RMI and Techno-Funda Insights
-
Stock Trading
ROC Made Easy: Master Course for ROC Stock Indicator
-
Stock Trading
Heikin Ashi Trading Tactics: Master the Art of Trading
-
Stock Trading
RSI Made Easy: RSI Trading Course
-
Stock Trading
Introduction to Technical Analysis & Candlestick Theory
The complex hospital generics segment grew 14% YoY to Rs 654 crore led by volume growth in inhalation anesthesia portfolio and India consumer health business gained 10% to Rs 278 crore.”FY25 so far has been a steady year for the company with revenue growth of 14% and EBITDA growing at 20%,” said Nandini Piramal, chairperson, Piramal Pharma.
“Our CDMO business continues to deliver robust performance with 18% revenue growth along with EBITDA margin improvement in 9MFY25 – this performance was largely led by innovation related work. Our CHG business registered an early-teen revenue growth during the quarter on the back of strong volume growth in our Inhalation Anesthesia portfolio. In our ICH business, power brands continue to register about 19% growth,” Piramal added.
